Scientific article

Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir

Published inAntiviral therapy, vol. 11, no. 5, p. 631-635
Publication date2006

BACKGROUND: There are few data on the selection of resistance by ritonavir-boosted saquinavir (SQV/r), particularly in antiretroviral (ARV)-naive patients. OBJECTIVE: To assess the incidence of virological failure and evolution of resistance in ARV-naive individuals receiving SQV/r in the induction phase of the Staccato trial. METHODS: ARV-naive subjects (n = 272) received SQV/r 1,600/100 mg once daily with two nucleoside reverse transcriptase inhibitors (NRTIs) for at least 24 weeks. Patients were defined as having virological failure (VF) when there were two consecutive HIV-1 RNA measurements > 500 copies/ml after week 12. Viral genotypes (reverse transcriptase [RT] and protease [PRO]) were determined at baseline in all patients and as close as possible to the time of initial failure in patients experiencing VF. RESULTS: VF was observed in 9/272 patients receiving SQV/r 1,600/100 mg once daily with two NRTIs (3.3%) and occurred 19-48 weeks after treatment initiation. Eight of these patients were evaluable at failure. No major PRO mutations were detected, but 2/8 displayed single new minor PRO substitutions (M36I, L10I) at VF that were known or suspected not to have been present at baseline; both these substitutions exist as natural polymorphisms. A third patient displayed a single new RT mutation (M184I). CONCLUSIONS: SQV/r plus two NRTIs (1,600/100 mg once daily) is an effective initial treatment option for ARV-naive patients, resulting in a low rate of viral rebound (3.3%). Furthermore, no major protease mutations were detected following VF, suggesting that future treatment options are preserved.

  • Adult
  • Antiretroviral Therapy, Highly Active
  • Drug Resistance, Viral/ genetics
  • Female
  • Genotype
  • HIV Infections/ drug therapy/enzymology/virology
  • HIV Protease/ genetics/metabolism
  • HIV Protease Inhibitors/ therapeutic use
  • HIV Reverse Transcriptase/antagonists & inhibitors/ genetics/metabolism
  • HIV-1/enzymology/ genetics
  • Humans
  • Male
  • Mutation
  • Reverse Transcriptase Inhibitors/therapeutic use
  • Ritonavir/ therapeutic use
  • Saquinavir/ therapeutic use
  • Thailand
  • Treatment Failure
  • Viral Load
Citation (ISO format)
ANANWORANICH, Jintanat et al. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. In: Antiviral therapy, 2006, vol. 11, n° 5, p. 631–635.
Updates (1)
ISSN of the journal1359-6535

Technical informations

Creation06/21/2010 10:23:06 AM
First validation06/21/2010 10:23:06 AM
Update time03/14/2023 3:42:38 PM
Status update03/14/2023 3:42:37 PM
Last indexation10/18/2023 9:19:07 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack